{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:54:21Z","timestamp":1777114461743,"version":"3.51.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer, a prevalent malignancy among women, is primarily categorized into four subtypes based on immunohistochemistry: luminal A breast cancer, luminal B breast cancer, HER2-enriched breast cancer, and triple-negative breast cancer (TNBC). Molecular targets for TNBC therapy are lacking, and TNBC is characterized by a high risk of recurrence and a poor prognosis. The advent of immune checkpoint inhibitors (ICIs), including PD-1, PD-L1, and CTLA-4 inhibitors, has led to therapeutic advances in the management of TNBC. The combination of chemotherapy and immunotherapy has been shown to improve patient outcomes and survival rates. This case primarily discusses immunotherapy combination treatments for PD-L1-negative TNBC patients, for which research remains relatively scarce. This case report focuses on a 48-year-old female patient with PD-L1-negative stage IV TNBC who exhibited a significant therapeutic response to cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody, in combination with chemotherapy, achieving a partial response (PR), as assessed by clinical evaluation. The tumor volume was reduced by more than 75%. The patient experienced grade 3 neutropenia, grade 2 thrombocytopenia, grade 2 nausea, and grade 2 immune-related adverse events, including pruritus and hyperthyroidism. Furthermore, this report reviews the current principal treatment modalities for TNBC. Particular emphasis was placed on discussing immunotherapy combination treatments for TNBC. Additional studies with larger cohorts are warranted for comprehensive translational research on PD-L1-negative TNBC, aiming to validate the efficacy and elucidate the mechanisms of action of various ICIs. This case highlights that dual-targeted therapy may provide a promising therapeutic option for patients with PD-L1-negative TNBC.<\/jats:p>","DOI":"10.3389\/fonc.2026.1764908","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:19:30Z","timestamp":1774588770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["PD-L1-negative triple-negative breast cancer exhibited a remarkable response to cadonilimab: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Baohua","family":"Chen","sequence":"first","affiliation":[{"name":"2nd Inpatient Area of Oncology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Jia","sequence":"additional","affiliation":[{"name":"2nd Inpatient Area of Oncology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjun","family":"Meng","sequence":"additional","affiliation":[{"name":"2nd Inpatient Area of Oncology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanjun","family":"Hu","sequence":"additional","affiliation":[{"name":"2nd Inpatient Area of Oncology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177202","article-title":"Advancements in clinical research and emerging therapies for triple-negative breast cancer treatment","volume":"988","author":"Xu","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001799","article-title":"Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001586","article-title":"Research hotspots and frontiers of neoadjuvant therapy in triple-negative breast cancer: a bibliometric analysis of publications between 2002 and 2023","volume":"110","author":"Yang","year":"2024","journal-title":"Int J Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00679-7","article-title":"Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC","volume":"10","author":"Im","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6661406","article-title":"Current and future perspectives of PD-1\/PDL-1 blockade in cancer immunotherapy","volume":"2021","author":"Makuku","year":"2021","journal-title":"J Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s40001-024-01901-9","article-title":"Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer","volume":"29","author":"Jama","year":"2024","journal-title":"Eur J Med Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1186\/s12885-024-13105-9","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188593","article-title":"Progress and challenges of immunotherapy in triple-negative breast cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1146905","article-title":"Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis","volume":"13","author":"Alifu","year":"2023","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-2182","article-title":"A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3162","article-title":"Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104\u2013202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): a phase 1\/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102939","article-title":"Enhancing radiotherapy techniques for triple-negative breast cancer treatment","volume":"136","author":"Sarlak","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e91737","DOI":"10.7554\/elife.91737","article-title":"Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: a pilot study","volume":"12","author":"Chen","year":"2023","journal-title":"Elife"},{"key":"B25","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/bcr3685","article-title":"Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients","volume":"16","author":"Takahashi","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.21203\/rs.3.rs-3903179\/v1","article-title":"High CTLA-4 gene expression is an independent good prognosis factor in breast cancer patients, especially in the HER2-enriched subtype","volume":"24","author":"Montoyo-Pujol","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/bctt.s506949","article-title":"Current status of breast cancer immunotherapy and prognosis-related markers","volume":"17","author":"Xu","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1182030","article-title":"Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.03.189","article-title":"Good response of cadonilimab (PD-1\/CTLA-4 bi-specific antibody) to patients with advanced lung adenocarcinoma after immunotherapy resistance: a case report","volume":"47","author":"An","year":"2024","journal-title":"Asian J Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101785","article-title":"Patient with HR-proficient advanced ovarian cancer achieved a complete response with cadonilimab combined chemotherapy (PD-1\/CTLA-4 bispecific): a case report and literature review","volume":"60","author":"Zhang","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1494138","article-title":"A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0779","article-title":"Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1","volume":"350","author":"Vacchelli","year":"2015","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of immunotherapy in triple-negative breast cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options","volume":"237","author":"So","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256360","article-title":"Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-sitc2021.289","article-title":"Cadonilimab, an anti-PD1\/CTLA4 bi-specific antibody with FC effector null backbone","volume":"9","author":"Huang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-1316","article-title":"Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade","volume":"30","author":"Mariniello","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/2326-6066.cir-17-0356","article-title":"Robust antitumor responses result from local chemotherapy and CTLA-4 blockade","volume":"6","author":"Ariyan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1615\/critrevimmunol.2019031554","article-title":"Back to the light side: the role of mechanotransduction in the paradoxical response to checkpoint inhibitors in cancer patients","volume":"39","author":"Abbas","year":"2019","journal-title":"Crit Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764908\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:19:31Z","timestamp":1774588771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764908\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":47,"alternative-id":["10.3389\/fonc.2026.1764908"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1764908","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1764908"}}